Advanced search
Publication Cover
Expert Opinion on Therapeutic Targets Volume 25, 2021 - Issue 12
Submit an article Journal homepage
1,002
Views
8
CrossRef citations to date
0
Altmetric
Review

PNPLA3 as a therapeutic target for fatty liver disease: the evidence to date

Alessandro Cherubinia Precision Medicine - Department of Transfusion Medicine and Hematology, Fondazione Irccs Ca’ Granda Ospedale Maggiore Policlinico, Milan, ItalyView further author information
,
Elia Casiratib Department of Pathophysiology and Transplantation, Università Degli Studi Di Milano, Milan, ItalyORCID Iconhttps://orcid.org/0000-0001-5938-0149View further author information
ORCID Icon,
Melissa Tomasia Precision Medicine - Department of Transfusion Medicine and Hematology, Fondazione Irccs Ca’ Granda Ospedale Maggiore Policlinico, Milan, ItalyView further author information
&
Luca Valentia Precision Medicine - Department of Transfusion Medicine and Hematology, Fondazione Irccs Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy;b Department of Pathophysiology and Transplantation, Università Degli Studi Di Milano, Milan, ItalyCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-8909-0345View further author information
ORCID Icon
Pages 1033-1043 | Received 30 Jun 2021, Accepted 10 Dec 2021, Published online: 22 Dec 2021

Citations (8)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Matthias Ocker & Daniel Neureiter. (2023) Gene expression inhibitors for the treatment of liver fibrosis: drugs under preclinical and early clinical investigation. Expert Opinion on Investigational Drugs 0:0, pages 1-9.
Read now

Articles from other publishers (7)

Frank Tacke, Tobias Puengel, Rohit Loomba & Scott L. Friedman. (2023) An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH. Journal of Hepatology 79:2, pages 552-566.
Crossref
Joost Boeckmans, Alexandra Gatzios, Jörn M. Schattenberg, Ger H. Koek, Robim M. Rodrigues & Tamara Vanhaecke. (2023) PNPLA3 I148M and response to treatment for hepatic steatosis: A systematic review . Liver International 43:5, pages 975-988.
Crossref
Alessandro Mantovani, Serena Pelusi, Sara Margarita, Francesco Malvestiti, Michela Dell'Alma, Cristiana Bianco, Luisa Ronzoni, Daniele Prati, Giovanni Targher & Luca Valenti. (2023) Adverse effect of PNPLA3 p.I148M genetic variant on kidney function in middle‐aged individuals with metabolic dysfunction . Alimentary Pharmacology & Therapeutics.
Crossref
Qian-Qian Zhou, Hai-Tao Xiao, Fan Yang, Yong-Dan Wang, Ping Li & Zu-Guo Zheng. (2023) Advancing targeted protein degradation for metabolic diseases therapy. Pharmacological Research 188, pages 106627.
Crossref
Damien Chua, Zun Siong Low, Guo Xiang Cheam, Aik Seng Ng & Nguan Soon Tan. (2022) Utility of Human Relevant Preclinical Animal Models in Navigating NAFLD to MAFLD Paradigm. International Journal of Molecular Sciences 23:23, pages 14762.
Crossref
Nuria Perez-Diaz-del-Campo, Diego Martínez-Urbistondo, Elisabetta Bugianesi & J. Alfredo Martínez. (2022) Diagnostic scores and scales for appraising Nonalcoholic fatty liver disease and omics perspectives for precision medicine. Current Opinion in Clinical Nutrition & Metabolic Care 25:5, pages 285-291.
Crossref
Xiaohan Xu, Kyle L. Poulsen, Lijuan Wu, Shan Liu, Tatsunori Miyata, Qiaoling Song, Qingda Wei, Chenyang Zhao, Chunhua Lin & Jinbo Yang. (2022) Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH). Signal Transduction and Targeted Therapy 7:1.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.